Atrial Fibrillation Management
Introduction to Atrial Fibrillation
- The decision to pharmacologically interrupt every episode of atrial fibrillation (AF) depends mainly on the severity of symptoms and the patient's hemodynamic stability, not on the mere presence of the arrhythmia 1, 2, 3
When Not to Interrupt Atrial Fibrillation
- In patients with brief or minimally symptomatic episodes of paroxysmal AF, it is reasonable to avoid antiarrhythmic drugs to prevent recurrences 1, 2, 3
- Self-limiting episodes of AF do not require antiarrhythmic therapy unless AF is associated with severe symptoms related to hypotension, myocardial ischemia, or heart failure 1, 2, 3
When Cardioversion is Necessary
- Immediate electrical cardioversion is recommended in patients with AF and hemodynamic instability, including symptomatic hypotension, acute myocardial infarction, angina, or heart failure that does not respond promptly to pharmacological measures 4
Strategy for Symptomatic Atrial Fibrillation
- For selected patients with symptomatic paroxysmal AF and no structural heart disease, the "pill-in-the-pocket" strategy involves self-administering a single oral dose of a drug soon after the onset of symptomatic AF 5, 6
- This approach improves quality of life, reduces hospital admissions, and costs 5, 6
Requirements for Outpatient Use
- Before using flecainide or propafenone outside the hospital, an initial conversion trial in the hospital is necessary to verify the safety of the treatment 5, 6
- Patients must be without sinus node or AV dysfunction, bundle branch block, prolonged QT interval, Brugada syndrome, or structural heart disease 5, 6
- A beta-blocker or non-dihydropyridine calcium antagonist must be administered at least 30 minutes before the class IC antiarrhythmic agent, or prescribed as ongoing baseline therapy, to prevent rapid AV conduction in case of conversion to atrial flutter 5, 6
Timing of Elective Cardioversion
- If the duration of AF is >48 hours or unknown, delay cardioversion and provide at least 3 weeks of therapeutic anticoagulation before, and continue for at least 4 weeks after 4
- For AF duration <48 hours in stable patients, cardioversion can be performed without prolonged anticoagulation, but with peri-procedural intravenous heparin 4
Rate Control as a Valid Alternative
- Rate control with anticoagulation is the preferred initial approach for most patients, particularly the elderly, minimally symptomatic, or with permanent AF 8
- Beta-blockers (metoprolol, atenolol) are first-line agents for patients with left ventricular ejection fraction (LVEF) >40% 8
- For patients with LVEF ≤40% or heart failure, beta-blockers and/or digoxin are recommended 8
Common Pitfalls to Avoid
- Do not use antiarrhythmic drugs in patients with advanced conduction disorders unless anti-bradycardia pacing is provided 8, 7
- Monitor the proarrhythmic effects of antiarrhythmic drugs, especially in patients with structural heart disease, prolonged QTc, or electrolyte abnormalities 8, 7
- All patients with recurrent AF and a CHA₂DS₂-VASc score ≥2 require oral anticoagulation regardless of sinus rhythm maintenance, as stroke risk is determined by underlying risk factors, not the current rhythm 8
- Direct oral anticoagulants (DOACs) are preferred over warfarin due to lower intracranial hemorrhage rates by 60-80% 8